Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Roche eye drug fails...

    Roche eye drug fails late-stage trial in blow to pipeline

    Written by Ruby Khatun Khatun Published On 2017-09-11T09:32:09+05:30  |  Updated On 18 Aug 2021 2:11 PM IST
    Roche eye drug fails late-stage trial in blow to pipeline

    ZURICH: A drug Roche had hoped would prevent loss of vision and become a big seller failed a late-stage trial, leading some analysts to say on Friday it now had no future.


    Lampalizumab, which was being trialed to treat a form of age-related macular degeneration, did not reduce changes in lesion area compared to a placebo after a year, Roche said.


    The Basel-based company said it had halted further doses until a second phase III study's results can be evaluated, which is likely to be around November.


    However, some analysts are already writing off lampalizumab, saying the second trial is not likely to turn out better.


    Lampalizumab is among Roche's stable of new medicines it is pushing toward the market in hopes of offsetting the impact of cheaper copies of its biggest sellers - the $20-billion-per-year trio of cancer drugs Herceptin, Avastin, and Rituxan - that are starting to hit the market.


    Its failure in tests is the latest in a string of disappointing trial results delivered by Roche drugs this year, taking some of the shine off its portfolio of up-and-coming medicines.


    "While this result is disappointing, we will continue to evaluate results...to get a clearer understanding of the data as we await the results of our second phase III study, Chroma, anticipated in November," Sandra Horning, Roche's chief medical officer, said in a statement.


    Progressive and irreversible geographic atrophy affects more than 5 million people worldwide, impairing reading, driving, recognizing faces, and activities in a dim or low light.



    LITTLE SCOPE


    The drug represents a big opportunity for Roche since there are no approved therapies for this condition.


    According to average estimates collected by Reuters, Lampalizumab had been forecast by analysts to hit $1.5 billion in annual sales by 2023, if it wins regulatory approval.


    Now, some analysts who had been counting on, even more, are already writing it off, even before the second trial.


    "There appears little scope for a positive outcome given the identical design of both trials," said Deutsche Bank's Tim Race, who had estimated peak annual sales exceeding 2 billion francs.


    "We now see a limited prospect of the drug reaching the market in the near future and have removed its sales from our forecasts."




    Reporting by John Miller; editing by Alexander Smith



    Avastincancerdrugseye drugfailsHerceptinLampalizumablate-stage trialmacular degenerationRituxanRocheSandra Horning
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok